Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aprela bazedoxifene/conjugated estrogens: Phase III data

In a double-blind Phase III trial in 332 postmenopausal women, Aprela met the primary endpoint

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE